Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis

ABSTRACT Introduction Nerandomilast, a phosphodiesterase-4B (PDE4B) preferential inhibitor, was approved in 2025 for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). PDE4 enzymes play a central role in regulating intracellular cyclic adenosine monophosphate (cAMP) and are h...

A. Tyker, N. Kuse, B. Pertzov et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.